A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

NCT05996848 · Completed

Last updated 2026-05-28

This study is testing whether the medication CagriSema helps adults in China who are overweight or obese lose weight compared to a placebo.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 300 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-08 · est. completion 2025-02

Where 37 sites · China

What this study is testing ClinicalTrials.gov NCT05996848 ↗

Description as written by the study sponsor.

This study will look at how well the new medicine CagriSema helps people with excess body weight losing weight compared to a "dummy" medicine and a medicine called semaglutide. Participants will either get CagriSema, a dummy medicine or semaglutide. Which treatment participants get is decided by chance. Participants will take one injection once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for about 1 year.

Treatments tested

Cagrilintide Drug

Participants will receive 2.4 mg cagrilintide subcutaneously.
Semaglutide Drug

Participants will receive 2.4 mg semaglutide subcutaneously.
Placebo Semaglutide Drug

Participants will receive placebo matched to semaglutide subcutaneously.
Placebo Cagrilintide Drug

Participants will receive placebo matched to cagrilintide subcutaneously.

Main thing measured	CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity or Overweight
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05996848 ↗